Emergent BioSolutions (EBS) Announces Pricing Of Offering Of $215 Million Of 2.875% Convertible Senior Notes
1/24/2014 9:13:23 AM
ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (“Emergent”) (NYSE: EBS) announced today the pricing of its offering of $215 million aggregate principal amount of 2.875% Convertible Senior Notes due 2021 (the “Notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), which was upsized from the previously announced $200 million offering. Emergent also granted the initial purchasers an option to purchase up to an additional $35 million aggregate principal amount of the Notes.
Help employers find you! Check out all the jobs and post your resume.
comments powered by